Ozempic vs Wegovy vs Mounjaro: Which GLP-1 Is Right for You?

Three names come up in nearly every conversation about weight loss medication: Ozempic, Wegovy, and Mounjaro. They dominate search results, social media, and waiting-room conversations alike — and for good reason. These medications have produced clinical trial results that were previously unachievable with pharmacotherapy alone.

But confusion is rampant. Many people don't realize that Ozempic and Wegovy contain the same active molecule at different doses, or that Mounjaro and Zepbound are the same drug with different brand names depending on what condition they're treating. This matters — because the choice between them isn't just a brand preference. It's a clinical decision based on your diagnosis, BMI, insurance coverage, and treatment goals.

This article breaks down each medication clearly, then answers the question patients actually ask: which one is right for me?

The Short Version: Same Category, Different Drugs

All three medications belong to a class called GLP-1 receptor agonists — drugs that mimic the gut hormone GLP-1 to reduce appetite, slow digestion, and improve blood sugar regulation. But they're not identical:

• Ozempic — semaglutide, FDA-approved for type 2 diabetes
• Wegovy — semaglutide at a higher dose, FDA-approved for chronic weight management
• Mounjaro / Zepbound — tirzepatide, a dual GIP/GLP-1 agonist, approved for both diabetes (Mounjaro) and weight management (Zepbound)

If you want the complete science behind how GLP-1 medications work, see our guide: What Are GLP-1 Medications? A Complete Guide to Semaglutide and Tirzepatide.

The Full Comparison Table

Ozempic: Diabetes Drug, Used Widely Off-Label

Ozempic was FDA-approved in 2017 for glycemic control in adults with type 2 diabetes, with an added indication for cardiovascular risk reduction in patients with established cardiovascular disease. It was not approved for weight management — but because semaglutide is an effective weight-loss agent, physicians began prescribing it off-label for that purpose before Wegovy received its weight-management approval in 2021.

Off-label prescribing is legal and common in medicine. The clinical concern, however, is that the approved doses for Ozempic (up to 2 mg/week) are lower than the 2.4 mg/week dose that produced the landmark STEP 1 weight-loss results. Patients using Ozempic off-label for weight loss are therefore using a lower dose than the evidence-based standard for weight management.

When Ozempic Makes Clinical Sense

• Patient has type 2 diabetes and wants weight loss — Ozempic directly addresses the primary diagnosis
• Insurance covers Ozempic for diabetes but not Wegovy for weight management (a very common situation)
• Physician judgment supports starting at lower semaglutide doses given patient-specific tolerability concerns

Wegovy: The Weight-Management Standard for Semaglutide

Wegovy is simply semaglutide at a higher weekly dose (up to 2.4 mg vs 2 mg for Ozempic), specifically approved for chronic weight management in adults with:

• BMI ≥ 30 (obesity), or
• BMI ≥ 27 (overweight) with at least one weight-related condition: hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease

STEP 1 Trial Results

The STEP 1 trial — semaglutide 2.4 mg vs placebo in adults with obesity but without diabetes — found:

• Average weight loss: 14.9% of body weight at 68 weeks
• 69% of semaglutide participants achieved ≥10% weight loss (vs 12% placebo)
• 33% achieved ≥20% weight loss

The SELECT trial (2023) demonstrated a 20% reduction in major adverse cardiovascular events in non-diabetic adults with overweight/obesity and established cardiovascular disease — the first weight-loss medication to show this benefit in a dedicated cardiovascular outcomes trial.

Mounjaro / Zepbound: The Newer, Higher-Efficacy Option

Tirzepatide — sold as Mounjaro for diabetes and Zepbound for weight management — is a dual GIP/GLP-1 receptor agonist. It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously. This dual mechanism appears to produce meaningfully greater appetite suppression and metabolic benefit than GLP-1 activation alone.

SURMOUNT-1 Trial Results

In SURMOUNT-1 — tirzepatide vs placebo in adults with obesity or overweight plus comorbidity, without diabetes:

• At 5 mg/week: average weight loss 15.0%
• At 10 mg/week: average weight loss 19.5%
• At 15 mg/week: average weight loss 20.9%
• 57% of patients on 15 mg achieved ≥20% weight loss — an outcome previously associated with bariatric surgery

Which Is Right for You? Decision Framework

The "best" GLP-1 medication is the one your physician prescribes based on your complete clinical picture. That said, here's how physicians typically think through the decision:

Side Effects: What the Three Medications Have in Common

Because all three drugs target the same or overlapping receptors, their side effect profiles are broadly similar. The most frequently reported effects are gastrointestinal, reflecting the mechanism of slowing gastric emptying:

• Nausea — most common, especially during dose escalation; typically improves after several weeks at a stable dose
• Vomiting — less common than nausea; usually transient
• Diarrhea or constipation — both can occur; often alternating
• Decreased appetite — the intended pharmacological effect; experienced as discomfort by some patients early on
• Fatigue — reported by some patients during initiation

Physicians manage these through gradual dose titration — both medications start at sub-therapeutic doses and increase over months. Most patients who complete the titration period find side effects diminish substantially.

Shared Contraindications

Both semaglutide and tirzepatide share the same primary contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC)
• History of Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Pregnancy — medication must be discontinued before attempting conception
• History of pancreatitis requires careful physician evaluation before prescribing

What About Compounded Versions?

During periods of shortage, FDA-registered compounding pharmacies were authorized to produce compounded semaglutide and tirzepatide. As of early 2025, the FDA has declared both branded products no longer in shortage, which substantially limits the legal basis for new compounded formulations.

Patients considering compounded GLP-1 products should discuss current regulatory status, manufacturing quality verification, and clinical implications with their physician. Brand-name products from licensed manufacturers have passed the full FDA approval process for safety, efficacy, and manufacturing standards.

How Telehealth Changes the Access Equation

Historically, obesity medicine specialists were difficult to access — long wait times, limited geographic availability, and frequent insurance denials for specialist referrals. Telehealth platforms have expanded access significantly: patients can complete eligibility assessments, consult with physicians via video, and receive prescriptions through the telehealth encounter, often with faster turnaround than in-person specialist visits.

PropPilot works with board-certified, licensed physicians trained in obesity medicine. All providers are independently credentialed and their licenses are publicly verifiable through state medical boards. Treatment requires a live video consultation — prescriptions are never issued without a face-to-face physician evaluation. Patient health information is handled in accordance with our Telehealth Consent and Privacy Policy.

Summary: The Comparison in Plain Language

• Ozempic = semaglutide for diabetes. Often prescribed off-label for weight loss. Lower maximum dose than Wegovy.
• Wegovy = semaglutide for weight management. Same molecule as Ozempic, higher approved dose (2.4 mg). ~15% average weight loss in trials.
• Mounjaro = tirzepatide for diabetes. Zepbound = tirzepatide for weight management. Dual GIP/GLP-1 mechanism. ~20% average weight loss at maximum dose in trials — currently the highest of any approved medication.
• All three require once-weekly injection, physician prescription, and gradual dose titration.
• FDA weight-management eligibility: BMI ≥30, or BMI ≥27 with a qualifying comorbidity.
• Insurance coverage varies widely. Diabetes indications are more commonly covered than weight-management indications.
• Shared contraindications: MTC history, MEN2, pregnancy.

The right medication for you depends on your primary diagnosis, your BMI, your insurance coverage, your side-effect tolerance, and your physician's clinical judgment. The comparison above gives you the vocabulary to have that conversation.